Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs. This is based on ethynylphosphonamidates that prevent premature cleavage of the linker payload during circulation and increasing hydrophilicity of the ADC while keeping the distance between antibody and payload to a minimum.
88 
Let's personalize your content